Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine and Methylphenidate for Alcohol-Use Disorders
NCT03575403Phase 1Completed
- Start
- Sep 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of duloxetine and methylphenidate hydrochloride extended-release chewable tablet in alcohol use disorder (AUD) (3 arms). Primary endpoints: Reinforcing Effects (Pre-Alcohol Dose Consumption) at 4 weeks and Reinforcing Effects (Post-Alcohol Dose Consumption) at 4 weeks. Started Sep 2018; status: completed.
02
Drugs
duloxetinemethylphenidate hydrochloride extended-release chewable tablet
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT03575403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03575403.